CR7351A - Composicion de la preparacion que contiene el compuesto fisiologico activo de acido inestable el proceso para producirla - Google Patents

Composicion de la preparacion que contiene el compuesto fisiologico activo de acido inestable el proceso para producirla

Info

Publication number
CR7351A
CR7351A CR7351A CR7351A CR7351A CR 7351 A CR7351 A CR 7351A CR 7351 A CR7351 A CR 7351A CR 7351 A CR7351 A CR 7351A CR 7351 A CR7351 A CR 7351A
Authority
CR
Costa Rica
Prior art keywords
composition
preparation
active compound
physiologically active
acid
Prior art date
Application number
CR7351A
Other languages
English (en)
Inventor
Aoki Shigeru
Original Assignee
Esai R & D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esai R & D Man Co Ltd filed Critical Esai R & D Man Co Ltd
Publication of CR7351A publication Critical patent/CR7351A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se intenta divulgar la composicion de la preparacion que permita la produccion conveniente de composicion de preparacion de liberacion sostenida que contenga un compuesto fisiologicamente activo inestable en acido y que tenga las propiedades deseadas de liberacion sostenida. A saber, la composicion de la preparacion que comprende una masa central que contiene un compuesto fisiologicamente activo inestable en acido y una capa con la que la masa central esta cubierta y que contiene una mezcla de un polimero insoluble en agua y un polimero enterico. La composicion de la preparacion de acuerdo a la presente invencion hace posible mantener una concentracion efectiva de sangre del compuesto fisiologicamente activo durante largo tiempo, mejorando asi su efecto terapeutico. Ademas, la composicion de acuerdo a la presente invencion permanece estable durante el almacenamiento prolongado.
CR7351A 2001-11-21 2004-05-20 Composicion de la preparacion que contiene el compuesto fisiologico activo de acido inestable el proceso para producirla CR7351A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001356018 2001-11-21

Publications (1)

Publication Number Publication Date
CR7351A true CR7351A (es) 2005-05-12

Family

ID=19167613

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7351A CR7351A (es) 2001-11-21 2004-05-20 Composicion de la preparacion que contiene el compuesto fisiologico activo de acido inestable el proceso para producirla

Country Status (25)

Country Link
EP (1) EP1454634A4 (es)
JP (1) JP4540092B2 (es)
KR (1) KR20050044545A (es)
CN (2) CN1589156A (es)
AP (1) AP1919A (es)
AU (1) AU2002366029B2 (es)
BR (1) BR0214372A (es)
CA (1) CA2466726C (es)
CO (1) CO5580800A2 (es)
CR (1) CR7351A (es)
EC (1) ECSP045110A (es)
HU (1) HUP0402323A3 (es)
IL (2) IL161983A0 (es)
IS (1) IS7266A (es)
MA (1) MA26346A1 (es)
MX (1) MXPA04004775A (es)
NO (1) NO20042563L (es)
NZ (1) NZ532907A (es)
RO (1) RO122395B1 (es)
RU (1) RU2311906C2 (es)
SI (1) SI21447A (es)
TW (1) TWI302461B (es)
UA (1) UA76256C2 (es)
WO (1) WO2003043661A1 (es)
ZA (1) ZA200403551B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
NZ549838A (en) * 2004-03-26 2010-04-30 Eisai R&D Man Co Ltd Coated controlled-release preparation containing a gastric acid secretion inhibitor
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
US20080213381A1 (en) * 2005-03-14 2008-09-04 Pharmaceutical Industries Limited Oral Drug Delivery System
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
RU2414889C2 (ru) * 2007-11-16 2011-03-27 Общество С Ограниченной Ответственностью "Технология Лекарств" Фармацевтическая композиция для лечения язвы желудка и двенадцатиперстной кишки в форме твердых желатиновых капсул, содержащая рабепразол или его производные, и способ ее получения
CN101878041A (zh) * 2007-11-27 2010-11-03 大原药品工业株式会社 颗粒制剂的制造方法
CN101822671A (zh) * 2009-03-06 2010-09-08 信谊药厂 雷贝拉唑组合物及其制备方法
CN102958515A (zh) 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
NZ605562A (en) * 2010-07-09 2013-11-29 Teijin Pharma Ltd Deuterated benzylbenzene derivatives and methods of use
JP2018184360A (ja) * 2017-04-25 2018-11-22 ニプロ株式会社 経口投与用の腸溶性徐放性製剤
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS5944311A (ja) * 1982-09-07 1984-03-12 Santen Pharmaceut Co Ltd 徐放性顆粒およびその製造法
ATE124864T1 (de) * 1989-03-10 1995-07-15 Yamanouchi Pharma Co Ltd Die wirkstoffabgabe steuerndes überzugsmaterial für lang wirksame formulierungen.
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
EP0447168A3 (en) * 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
JPH0826977A (ja) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd 溶出制御型経口製剤
JPH09323926A (ja) * 1996-03-15 1997-12-16 Nikken Chem Co Ltd バルプロ酸ナトリウムの徐放性錠剤
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
WO1999053918A1 (en) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
DE69934505T2 (de) * 1998-05-18 2007-10-04 Takeda Pharmaceutical Co. Ltd. Im munde zerfallende tablette enthaltend ein benzimidazole
JP2001055322A (ja) * 1999-08-18 2001-02-27 Tanabe Seiyaku Co Ltd パルス放出型製剤
AU782538B2 (en) * 1999-10-20 2005-08-04 Eisai Co. Ltd. Method for stabilizing benzimidazole compounds
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems

Also Published As

Publication number Publication date
AP1919A (en) 2008-11-13
JPWO2003043661A1 (ja) 2005-03-10
HUP0402323A3 (en) 2008-04-28
CN1589156A (zh) 2005-03-02
SI21447A (sl) 2004-10-31
ZA200403551B (en) 2005-07-07
AU2002366029B2 (en) 2008-01-31
CN101982199A (zh) 2011-03-02
CA2466726A1 (en) 2003-05-30
UA76256C2 (en) 2006-07-17
TW200300353A (en) 2003-06-01
EP1454634A1 (en) 2004-09-08
AU2002366029A1 (en) 2003-06-10
NZ532907A (en) 2007-05-31
ECSP045110A (es) 2004-08-27
BR0214372A (pt) 2004-10-26
CO5580800A2 (es) 2005-11-30
JP4540092B2 (ja) 2010-09-08
IL161983A0 (en) 2005-11-20
AP2004003045A0 (en) 2004-06-30
NO20042563L (no) 2004-06-18
CA2466726C (en) 2011-02-22
IS7266A (is) 2004-05-14
RU2004118495A (ru) 2005-03-20
WO2003043661A1 (fr) 2003-05-30
MXPA04004775A (es) 2005-02-17
RO122395B1 (ro) 2009-05-29
TWI302461B (en) 2008-11-01
KR20050044545A (ko) 2005-05-12
MA26346A1 (fr) 2004-10-01
HUP0402323A2 (hu) 2005-02-28
IL161983A (en) 2009-11-18
EP1454634A4 (en) 2007-05-30
RU2311906C2 (ru) 2007-12-10

Similar Documents

Publication Publication Date Title
CR7351A (es) Composicion de la preparacion que contiene el compuesto fisiologico activo de acido inestable el proceso para producirla
ES2262173T3 (es) Potenciadores de la penetracion dermica y sistemas de aporte de farmacos que los utilizan.
CN103547258B (zh) 局部一氧化氮系统及其使用方法
ES2432241T3 (es) Composición estabilizada que comprende al menos un compuesto adrenérgico
PE20030399A1 (es) Formas de administracion de propiverina o sus sales farmaceuticamente aceptables con liberacion prolongada de la sustancia activa
GT199900072A (es) Jarabe antihistaminico estabilizado.
ES2135723T3 (es) Uso de esteres de acidos grasos como sustancias bioadhesivas.
ES2142644T3 (es) Procedimiento para la obtencion de una disolucion de infusion y dialisis que contiene bicarbonato.
ES2155473T3 (es) Composicion veterinaria que contiene un inhibidor de las bombas de protones.
SV2004001418A (es) Formulaciones farmaceuticas de 5,7,14-triazaciclo 10.3.1.0.2,11.04,9) -hexadeca-2(11),3,5,7,9-pentaeno" ref.pc 23248
ATE387937T1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer und hydroxynaphthalin-carbonsäure, sowie deren herstellung
CY1108992T1 (el) Η χρηση του υαλουρονικου οξεος για την παρασκευη συνθεσεων για τη θεραπευτικη αντιμετωπιση υποτροπιαζουσων αφθων της στοματικης κοιλοτητας
RU2010117170A (ru) Пенящаяся фторсодержащая композиция для ухода за полостью рта
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
BR0013357A (pt) Vacina
AR037048A1 (es) Agentes antidisritmicos administrados vaginalmente para tratar el dolor pelvico
NO20023875D0 (no) Stabilt nasalt, oralt eller sublingualt anvendbart preparat
DE60123100D1 (de) Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
CA2425218A1 (en) Pharmaceutical solutions of modafinil compounds
CY1106055T1 (el) Τυποποιηση των υποκατεστημενων βενζιμιδαζολων
BR0210224A (pt) Formas de dosagem projetada para ser engolida diretamente e apresentada como uma formulação em comprimido ou cápsula deglutìvel, e, processo para preparação de uma forma de dosagem
AR048050A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
BRPI0411832A (pt) forma de administração em forma de pelìcula para a administração transmucosa de substáncias ativas, uso da forma de administração e processo para a produção de uma forma de administração
ES2099649T3 (es) Nueva composicion farmaceutica destinada para la fabricacion de un polvo estable que contiene, a titulo de ingrediente activo, una asociacion de acido acetilsalicilico y de metoclopramida.